Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

Szczegóły
Abstrakt

Tytuł:: Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.
Autorzy:: He R; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Zheng M; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Lian L; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Yao X; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Źródło:: Cells [Cells] 2021 May 17; Vol. 10 (5). Date of Electronic Publication: 2021 May 17.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI
MeSH Terms:: Disability Evaluation*
Health Status Indicators*
Amyotrophic Lateral Sclerosis/*diagnosis
Adult ; Aged ; Amyotrophic Lateral Sclerosis/mortality ; Amyotrophic Lateral Sclerosis/physiopathology ; Amyotrophic Lateral Sclerosis/psychology ; China ; Communication ; Deglutition ; Disease Progression ; Female ; Health Status ; Humans ; Longitudinal Studies ; Male ; Mental Health ; Middle Aged ; Neuropsychological Tests ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Respiration ; Self Care ; Severity of Illness Index ; Time Factors ; Walking
References:: Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):512-9. (PMID: 26203659)
J Neurol. 2020 Mar;267(3):607-615. (PMID: 31696295)
Neurol Sci. 2015 Dec;36(12):2243-52. (PMID: 26205535)
J Neurol. 2015 Jun;262(6):1407-23. (PMID: 25385051)
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):294-301. (PMID: 30467209)
Rev Neurol (Paris). 2019 May;175(5):277-282. (PMID: 30606512)
Ann Neurol. 2009 Aug;66(2):235-44. (PMID: 19743457)
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):378-83. (PMID: 19922128)
Front Neurol. 2018 Jun 19;9:442. (PMID: 29971035)
Neurology. 2019 Sep 3;93(10):e984-e994. (PMID: 31409738)
Muscle Nerve. 2020 Feb;61(2):218-221. (PMID: 31621933)
J Neurol Sci. 1999 Oct 31;169(1-2):13-21. (PMID: 10540002)
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1038-1043. (PMID: 30045943)
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):38-44. (PMID: 24336810)
Nat Sci Sleep. 2019 Aug 09;11:97-111. (PMID: 31496852)
JAMA Neurol. 2017 May 1;74(5):525-532. (PMID: 28264096)
Neurology. 2018 Oct 9;91(15):e1370-e1380. (PMID: 30209236)
Front Neurol. 2019 May 22;10:523. (PMID: 31191429)
Int Rev Neurobiol. 2017;134:1409-1441. (PMID: 28805578)
Lancet. 2017 Nov 4;390(10107):2084-2098. (PMID: 28552366)
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):227-232. (PMID: 28054828)
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):45-9. (PMID: 24463480)
Neurology. 2019 Dec 10;93(24):e2294-e2305. (PMID: 31740545)
J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1180-5. (PMID: 25886781)
Acta Neurol Scand. 2014 Aug;130(2):111-7. (PMID: 24689740)
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jun;16(3-4):230-6. (PMID: 25548957)
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):358-65. (PMID: 26962892)
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):291-297. (PMID: 31871138)
Brain. 2012 Mar;135(Pt 3):847-52. (PMID: 22271664)
Lancet. 2011 Mar 12;377(9769):942-55. (PMID: 21296405)
J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1051-2. (PMID: 26134851)
J Neurol. 2016 Jun;263(6):1129-36. (PMID: 27083563)
Lancet Neurol. 2018 May;17(5):423-433. (PMID: 29598923)
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):414-25. (PMID: 26864085)
Eur J Neurol. 2016 Sep;23(9):1426-32. (PMID: 27238551)
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):53-60. (PMID: 30784318)
J Neurol Sci. 2019 Feb 15;397:92-95. (PMID: 30597420)
Grant Information:: 82001332 the Young Scientist Fund of National Natural Science Foundation of China; 2017YFC0907703 the National Key Research and Development Program of China; N/A Guangdong Provincial Engineering Center For Major Neurological Disease Treatment; N/A Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease; N/A Guangdong Provincial Clinical Research Center for Neurological Diseases; 2015B050501003 the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases
Contributed Indexing:: Keywords: Milano–Torino staging; amyotrophic lateral sclerosis; long-term survival; neuropsychiatric factors
Entry Date(s):: Date Created: 20210602 Date Completed: 20211026 Latest Revision: 20211026
Update Code:: 20240104
PubMed Central ID:: PMC8156970
DOI:: 10.3390/cells10051220
PMID:: 34067647
: Czasopismo naukowe

Pełny tekst

(1) Background: The aim of this longitudinal study was to evaluate the association between disease progression according to the Milano-Torino staging (MITOS) system and long-term survival in Chinese patients with amyotrophic lateral sclerosis (ALS). We also examined factors affecting MITOS progression. (2) Methods: Patients were enrolled and underwent follow-up at 6, 12, 18, and 24 months, and their demographic and clinical data, including the Milano-Torino stage, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score and neuropsychiatric data, were evaluated. The sensitivity and specificity of predicting survival outcomes based on MITOS progression and ALSFRS-R score decline from baseline to 6 months were compared. The associations between MITOS progression from baseline to 6 months and survival outcome at 12, 18 and 24 months were examined, and factors associated with disease progression were evaluated with subgroup analyses. (3) Results: Among the 100 patients included, 74% were in stage 0 at baseline, and approximately 95% progressed to a higher stage of the MITOS system at 24 months. MITOS progression from baseline to 6 months and ALSFRS-R decline showed comparable value for predicting survival at 12, 18, and 24 months. MITOS progression from baseline to 6 months is strongly associated with death outcomes. Older age at onset and increased depression and anxiety scores may be related to disease progression. (4) Conclusions: MITOS progression during the early disease course could serve as a prognostic marker of long-term survival and may have utility in clinical trials. Age at onset and diagnosis and neuropsychiatric factors might be associated with disease progression.

Informacja